Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With

Status Not yet recruiting

Clinical Trial Summary

Anti-Mullerian Hormone (AMH) is produced only in small ovarian follicles with quite stable levels during the cycle. There is not yet sufficient data to inform couples undergoing IVF about the effect of ovarian stimulation on the levels of AMH due to the increasing size of follicles and chances of success of the method.

Clinical Trial Description

Patients undergoing IVF will be included in the study. All patients will be counseled regarding their prognosis. Anti-Mullerian Hormone (AMH) will be measured prior to the initiation of IVF and during ovarian stimulation. Patients will be stimulated with a short GnRH-antagonist protocol. All women will have measurements of serum FSH and estradiol (E2) and a pelvic sonogram on the second day of their cycle. Ovarian stimulation will be initiated with of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH. The dose of gonadotropins will depend on the levels of estradiol and FSH prior stimulation. All patients will be re-evaluated on day 3 and 5 of the stimulation (measurment of AMH, E2 and pelvic sonogram), and dosage adjustments will be made and the antagonists (Cetrorelix or ganirelix 0.25 mg/day) will be initiated on day 5. Measurment of AMH, E2 and pelvic sonogram to conferm the size of follicles will be continue every second day untill the oocyte retrieval. When at least 2 follicles reach an average diameter of 17 mm, final oocyte maturation will be triggered with 10,000IU of hCG ( Pregnyl, Organon, Greece Inc.). Oocyte retrieval will be performed 34 to 36 hours later. Patients with successful fertilization will have embryo transfer under sonographic guidance on day 3 after retrieval. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02237781
Study type	Interventional
Source	University of Athens
Contact	Nikos Vlahos, MD
Phone	30 210 7286000
Email	nikosvlahos@med.uoa.gr
Status	Not yet recruiting
Phase	Phase 2/Phase 3
Start date	October 2014
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06239051` - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting	`NCT05179993` - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting	`NCT03767569` - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients	Phase 3
Completed	`NCT03737253` - Hormone Evaluation in Artificial Reproductive Technology	Phase 4
Not yet recruiting	`NCT02237755` - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.	Phase 2/Phase 3
Completed	`NCT01477073` - Multiple Dose FSH-GEX(TM) in Healthy Volunteers	Phase 1
Recruiting	`NCT00119925` - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"	N/A
Recruiting	`NCT06098495` - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed	`NCT03998553` - Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women	N/A
Completed	`NCT05189145` - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles	N/A
Recruiting	`NCT05050747` - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed	`NCT01620346` - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age	N/A
Completed	`NCT00315029` - Patient-Centered Implementation Trial for Single Embryo Transfer	N/A
Recruiting	`NCT03080584` - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients	N/A
Not yet recruiting	`NCT05106712` - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women	N/A
Recruiting	`NCT06041204` - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism	N/A
Completed	`NCT02328924` - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols?	Phase 4
Completed	`NCT01604044` - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.	Phase 1
Completed	`NCT04019899` - Myo-inositol and Vitamin D3 During IVF	N/A
Completed	`NCT02454829` - Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms